Melanoma Therapeutics Market Set for Double-Digit Growth Through 2034
The melanoma therapeutics market size was valued at $8.5 billion in 2025 and is projected to reach $21.7 billion by 2034, growing at a compound annual growth rate (CAGR) of 11.00%.
This forecast comes from Strategic Revenue Insights Inc., which notes that the market's steady double-digit growth can be attributed to the increasing incidence of melanoma worldwide. According to World Health Organization data, skin cancer is among the most common cancers diagnosed globally.
The report highlights the importance of immune checkpoint inhibitors in treating advanced melanoma, with Merck & Co.'s Keytruda and Bristol Myers Squibb's Opdivo leading the way. These treatments have significantly improved survival rates for patients with advanced melanoma, setting a bar that competitors continue to build against.
The report also emphasizes the growing adoption of combination therapies and biomarker-guided treatment selection, which are improving outcomes and reshaping how pharmaceutical companies prioritize R&D investment.